Yüklüyor......
Safety, pharmacokinetics and pharmacodynamics of idarucizumab, a specific dabigatran reversal agent in healthy Japanese volunteers: a randomized study
ESSENTIALS: Idarucizumab, a monoclonal antibody fragment, binds dabigatran with high affinity and specificity. In this phase 1 trial, healthy Japanese males received idarucizumab alone or with dabigatran. Idarucizumab achieved immediate, complete and sustained reversal of dabigatran anticoagulation....
Kaydedildi:
| Yayımlandı: | Res Pract Thromb Haemost |
|---|---|
| Asıl Yazarlar: | , , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
John Wiley and Sons Inc.
2017
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6058259/ https://ncbi.nlm.nih.gov/pubmed/30046691 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/rth2.12029 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|